Curated News
By: NewsRamp Editorial Staff
August 05, 2026
NeuroThera Launches Phase IIb Trial for Tourette Syndrome at Yale
TLDR
- NeuroThera Labs advances SCI-110 to Phase IIb at Yale, potentially gaining first-mover advantage in Tourette treatment.
- The Phase IIb trial is a randomized, double-blind, placebo-controlled cross-over study measuring tic severity via Yale Global Tic Severity Scale.
- SCI-110 offers hope for adults with Tourette Syndrome, aiming to reduce tics and improve quality of life with fewer side effects.
- SCI-110 combines dronabinol with palmitoylethanolamide, a unique formulation, and is now tested at three international sites.
Impact - Why it Matters
This news matters because Tourette Syndrome affects millions worldwide, yet current treatments are often inadequate, especially for adults with severe symptoms. SCI-110, if successful, could provide a novel and safer therapeutic option, potentially improving the quality of life for patients who have limited choices. The initiation of a U.S. site at a prestigious institution like Yale underscores the progress and credibility of the research, bringing hope for a new treatment that could address a significant unmet medical need.
Summary
NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage biotech company and majority-owned subsidiary of SciSparc Ltd., has announced the initiation of its Phase IIb clinical trial site at the Yale Child Study Center, Yale School of Medicine, in New Haven, Connecticut. The study, led by Dr. Michael H. Bloch, will evaluate SCI-110, the company’s proprietary cannabinoid-based drug candidate for treating Tourette Syndrome (TS) in adults. This launch marks a significant milestone in the global development program for SCI-110, which combines dronabinol with the endocannabinoid-like palmitoylethanolamide in a single dosage form designed to reduce tics and associated comorbid symptoms while minimizing side effects.
The Phase IIb trial is also underway at Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel. Building on positive Phase IIa results that showed an average tic reduction of 21% as measured by the Yale Global Tic Severity Scale Total Tic Score, this randomized, double-blind, placebo-controlled, cross-over trial will enroll adults aged 18-65. The primary endpoint is the change in tic severity at weeks 12 and 26 compared to baseline, with safety monitored through adverse events. Dr. Adi Zuloff-Shani, CTO of NeuroThera, emphasized the unmet medical need in TS and expressed belief in SCI-110's potential to offer a novel, more effective, and safer treatment approach.
For more information, contact Michal Efraty at michal@efraty.com. The company’s forward-looking statements are subject to risks detailed in its continuous disclosure documents on www.sedarplus.ca. The original release can be viewed at www.newmediawire.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroThera Launches Phase IIb Trial for Tourette Syndrome at Yale
